“…Enzymes from biosynthetic pathways to NcAAs ( Hedges and Ryan, 2020 ) are clear candidates for MECs expansion. On the other hand, information of specific enzymes for functionalization of AAs or AA transformation into other important pharmaceutical compounds is also accumulating in the literature (e.g., Smirnov et al, 2012 ; Busto et al, 2014 ; Hönig et al, 2017 ; Hyslop et al, 2018 ; Parthasarathy et al, 2018 ; Peters and Buller, 2019 ; McDonald et al, 2019 ; Hedges and Ryan, 2020 ; Mindt et al, 2020 ; Song et al, 2020 ; Wendisch, 2020 ; Zhang et al, 2020 ; Zhao et al, 2020 ). These enzymes are, in principle, complementary to well stablished NcAA-production MECs.…”